NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

末梢性T細胞淋巴瘤 (PTCL) - 市場考察,流行病學,市場預測:2030年

Peripheral T-Cell Lymphoma (PTCL)-Market Insights, Epidemiology and Market Forecast-2030

出版商 DelveInsight Business Research LLP 商品編碼 972400
出版日期 按訂單生產 內容資訊 英文 290 Pages
商品交期: 10個工作天內
價格
末梢性T細胞淋巴瘤 (PTCL) - 市場考察,流行病學,市場預測:2030年 Peripheral T-Cell Lymphoma (PTCL)-Market Insights, Epidemiology and Market Forecast-2030
出版日期: 按訂單生產內容資訊: 英文 290 Pages
簡介

本報告提供末梢性T細胞淋巴瘤 (PTCL) 調查分析,以過去·未來的流行病學,美國·歐洲5個國家 (德國,西班牙,義大利,法國,英國) ·日本的市場趨勢為焦點,提供目前治療方法,新藥,市場規模等相關的系統性資訊。

目錄

第1章 主要考察

第2章 末梢性T細胞淋巴瘤 (PTCL)的摘要整理

第3章 末梢性T細胞淋巴瘤 (PTCL) 市場概要

  • 2017年末梢性T細胞淋巴瘤 (PTCL)的市場佔有率分佈
  • 2030年末梢性T細胞淋巴瘤 (PTCL)的市場佔有率分佈

第4章 疾病的背景和概要:末梢性T細胞淋巴瘤 (PTCL)

  • 簡介
  • PTCL的分類
  • PTCL的亞型
  • 徵兆與症狀
  • PTCL的原因
  • 病理生理學
  • 其他症狀
  • 分期
  • 診斷

第5章 病例報告

第6章 流行病學和患者族群

  • 主要調查結果
  • KOL的見解
  • 流行病學技術
  • 主要7個國家的末梢性T細胞淋巴瘤 (PTCL)的全發病病例

第7章 美國的流行病學

  • 前提條件與理論的根據
  • 全發病病例
  • 各病期的發病病例
  • 各子類型的發病病例

第8章 歐洲5個國家的流行病學

  • 前提條件與理論的根據
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國

第9章 日本的流行病學

  • 前提條件與理論的根據
  • 全發病病例
  • 各病期的發病病例
  • 各子類型的發病病例

第10章 治療

  • 治療目標
  • 治療選擇
  • 未來的治療
  • 個體化治療和生物標記
  • 結論
  • 治療指南

第11章 未滿足需求

第12章 上市藥

第13章 新藥

第14章 市場分析末梢性T細胞淋巴瘤 (PTCL) :主要7個國家

第15章 末梢性T細胞淋巴瘤 (PTCL) 的CD30表現

第16章 新興治療的發表預定

第17章 屬性分析III期

第18章 屬性分析II期

第19章 美國市場預測

第20章 市場預測歐洲5個國家

第21章 日本市場預測

第22章 推動市場要素

第23章 市場障礙

第24章 SWOT分析

第25章 償付與市場進入

第26章 認可的設施

第27章 附錄

第28章 DelveInsight的服務內容

第29章 免責聲明

第30章 關於DelveInsight

目錄
Product Code: DIMI0092

DelveInsight's 'Peripheral T-Cell Lymphoma (PTCL)-Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the PTCL, historical and forecasted epidemiology as well as the PTCL market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The PTCL market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM PTCL market size from 2017 to 2030. The report also covers current PTCL treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030.

Peripheral T-Cell Lymphoma (PTCL) Disease Understanding and Treatment Algorithm

Peripheral T-Cell Lymphoma (PTCL) Overview

Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called "T cells" and "natural killer (NK) cells". It is PTCL's origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term "peripheral" does not refer to the extremities, but identifies PTCL as cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin.

PTCLs generally affects people aged 60 years and older and are diagnosed slightly more often in men than in women, however, younger adults and children are also diagnosed with PTCLs. PTCL is an uncommon disease in the United States, whereas some forms of PTCL are more common in Asia, Africa and the Caribbean. PTCL comprises about 10-15% of all NHL cases in the United States. The World Health Organization (WHO) classification system recognizes subtypes of PTCL and has grouped the diseases into three categories: nodal, extranodal and leukemic. WHO has also divided T-cell lymphomas into two groups: aggressive (fast-growing) and indolent (slow-growing). PTCLs are a varied group of diseases that differ from B-cell lymphomas since PTCLs are less common than B-cell lymphomas, they are not as well understood.

Peripheral T-Cell Lymphoma (PTCL) Diagnosis

Most PTCLs are diagnosed by taking a small sample (a "biopsy") of an enlarged lymph node and then examining the cells under a microscope. Generally, either the lymph node or a part of the lymph node, is surgically removed. The cells in many subtypes of PTCLs look alike; therefore, making an accurate diagnosis may require the use of additional diagnostic tests, including blood tests, CT (computerized axial tomography), PET (positron emission tomography) scans, MRI (magnetic resonance imaging), and bone marrow biopsy.

Peripheral T-cell Lymphoma (PTCL) Treatment

Currently, newly diagnosed PTCL patients are usually treated with anthracycline-based chemotherapy regimens. For most subtypes of PTCL, the initial treatment is typically a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone), or other multidrug regimens. Because most patients with PTCL will relapse, high-dose chemotherapy followed by an autologous stem cell transplant (in which patients receive their stem cells that are preemptively collected) is recommended. While promising, there is no firm clinical data to prove that undergoing a transplant in this setting is more beneficial than not undergoing a transplant.

Patients with relapsed disease are usually treated with combination chemotherapy such as ICE (ifosfamide, carboplatin, and etoposide) or other combination regimens, followed by stem cell transplantation. However, some regimens might not be suited for everyone because of high toxicity levels. Treatment for PTCL aims to cure and includes the use of combination chemotherapy regimens-typically CHOP based chemotherapy or EPOCH, localized radiotherapy, stem cell transplants and steroid therapy.

Peripheral T-cell Lymphoma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of PTCL, Stage-specific Incident Cases of PTCL, and Subtype-specific Cases of PTCL, a scenario of PTCL in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpses of the PTCL epidemiology in the 7MM.

  • The total incident population of PTCL in the seven major markets was 16,298 in 2017, which is expected to increase in the forecast period.
  • The United States accounted for the maximum incident population among the 7MM in 2017.
  • In EU5 countries, Germany accounted for the highest cases of PTCL while Spain had the lowest incident population in 2017.
  • The estimates suggest higher incidence of PTCL in the United States with 6,110 cases in 2017
  • The epidemiological model of DelveInsight estimates a higher proportion of PTCL cases was found in stage IV as compared to other stages in the United States. In 2017, stage I, stage II, stage III, and stage IV PTCL incident cases were 876, 727, 1,434, and 3,074 respectively.
  • PTCL-NOS accounts for 31% of all incident cases of PTCL followed by Anaplastic Large-Cell Lymphoma (ALCL) with 26% in the United States in year 2017. Other major subtypes include AITL Nasal NK/T-cell lymphoma, Enteropathy-type intestinal TCL, Hepatosplenic TCL and Others.
  • In 2017, the incident cases of PTCL-NOS, ALCL, AITL, nasal NK/T-cell lymphoma, enteropathy-type intestinal TCL, hepatosplenic TCL, and others in the United States were 1,917, 1,577, 1,380, 412, 179, 90, and 555 respectively.

Country Wise-PTCL Epidemiology

The epidemiology segment also provides the PTCL epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Peripheral T-cell Lymphoma Drug Chapters

This segment of the PTCL report encloses the detailed analysis of the mid- and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Peripheral T-cell Lymphoma Emerging Drugs

Denileukin diftitox: Eisai

Denileukin diftitox (DD) is a recombinant cytotoxic fusion protein which is being developed by Eisai. The drug is administered intravenously, that binds the enzymatically active portion of the diphtheria toxin to the receptor-binding domain of the interleukin-2 molecule, thereby targeting cells producing the IL-2 receptor. Denileukin diftitox is already approved with name, Ontak for Cutaneous T-cell Lymphoma. The drug candidate is in Phase II stage of development for Peripheral T-cell lymphoma (PTCL) in Japan.

Azacitidine (CC-486): Celgene Corporation

Azacitidine (CC-486) is being developed by Celgene Corporation. Azacitidine (CC-486) is an oral hypomethylating agent that incorporates into DNA and RNA, allowing sustained epigenetic regulation due to prolonged exposure. The main mechanism of action is thought to be hypomethylation of DNA, as well as direct cytotoxicity to abnormal hematopoietic cells in the bone marrow. Currently, the company is investigating the molecule in two phase III clinical trial for Relapsed or Refractory AITL, and phase II clinical trial for Previously Untreated PTCL.

HBI-8000: HUYA Bioscience International/ Quintiles

HBI-8000 (Chidamide/CS055), is a member of the benzamide class of histone deacetylase inhibitors (HDACIs), and HUYA Bioscience International is developing this molecule, as the first approved, oral class I selective HDACI. It works by controlling how tightly DNA is wound around histone proteins, which regulate gene expression. HHBI-8000 became the first benzamide HDAC inhibitor approved worldwide when the drug was approved for the treatment of PTCL in China, where it is now marketed under the trade name Epidaza. Currently, the company is investigating the molecule in phase II clinical trial in Japan, in patients with relapsed or refractory PTCL.

Copiktra (Duvelisib): Verastem

Copiktra (Duvelisib), is a targeted oral inhibitor of phosphoinositide 3-kinase developed by Verastem. The phosphoinositide 3-kinase (PI3K) signaling pathway is a key regulator of cancer proliferation (rapid increase or spread) and metastasis (development of secondary growths away from a primary site of cancer). Currently, the company is investigating the molecule in phase II PRIMO Study in patients with relapsed or refractory PTCL. The company is planning to build upon their existing Fast Track Designation and Orphan Drug Designation and submit a regulatory package to the US FDA to broaden the use of COPIKTRA and to include treatment of PTCL.

Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is an investigational humanized IgG4 anti-PD-1 monoclonal antibody, administered intravenously that is specifically designed to minimize binding to FcγR on macrophages. Currently, the molecule is under investigation in phase II clinical study, relapsed or refractory mature T- and NK- Neoplasms (nasal or non-nasal type, peripheral T-cell lymphoma - not otherwise specified, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, or Sezary syndrome).

Keytruda: Merck Sharp & Dohme Corp

Keytruda is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype against PD-1, designed to block its interaction with PD-L1 and PD-L2 directly which is developed by Merck. Moreover, pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the antitumor immune response.

SP-02 (Darinaparsin, ZIO-101): Solasia Pharma

A novel mitochondrial-targeted agent (organic arsenic) SP-02 is being developed by Solasia Pharma for the treatment of various hematologic and solid cancers. It is being developed to administer intravenously for the treatment of PTCL. The exact mechanism of darinaparsin is not known, but it appears to generate volatile cytotoxic arsenic compounds when glutathione (GSH) concentrations are low.

Ruxolitinib: Incyte/Novartis

Ruxolitinib is an orally administered selective kinase inhibitor that inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2. Incyte and Novartis together are developing Ruxolitinib, which is in phase II stage development for PTCL in collaboration with the University of Nebraska. Ruxolitinib is marketed under the brand name Jakafi for the treatment of Myelofibrosis, including Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis and post-essential Thrombocythemia Myelofibrosis.

Products detail in the report:

Peripheral T-cell Lymphoma Market Outlook

Treatment for PTCL aims to cure and includes the use of combination chemotherapy regimens, localized radiotherapy, stem cell transplants and steroid therapy, etc. It is most often treated with a combination of chemotherapies which includes CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOEP or EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone). In some cases, stem cell or bone marrow transplant is recommended at the end of combination chemotherapy.

There are only five FDA approved products for PTCL treatment, including Beleodaq (Belinostat, Acrotech Biopharma); Istodax (Romidepsin, Celgene), Folotyn (Pralatrexate, Acrotech Biopharma), Arranon (Nelarabine, GlaxoSmithKline), and Adcetris (Brentuximab vedotin, Seattle Genetics).

In the past years, with no current standard of care for patients with PTCL, there were no approved therapies for the first-line treatment. But recent approval of Adcetris (Brentuximab vedotin) in November 2018 from the US FDA has changed the market landscape. It is now the only FDA-approved regimen in first-line therapy used in combination with chemotherapy for adults with previously untreated systemic ALCL or other CD30-expressing PTCL.

Apart from the available approved therapies, there are some off-label therapies and other emerging therapies that are available for PTCL treatment. Some of the off-label therapies which have been listed in the NCCN guidelines for Relapsed PTCL are MabThera (Rituxan), Bortezomib, Bendamustine, Lenalidomide, and Alemtuzumab.

A study conducted by Abramson et al. (2014), determined the impact of PTCL therapies. The study included a retrospective analysis of 341 newly diagnosed PTCL patients from nine US academic centers diagnosed from January 2000 to December 2010. The outcome was compared with a matched cohort of diffuse large B-cell lymphoma (DLBCL) patients, and prognostic factors were assessed using unilabiate and multivariate analyses. The study shows that 7% of the patients received only palliative care whereas 318 received chemotherapy: CHOP-like regimens (70%), hyperCVAD/MA (hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone/methotrexate, cytarabine) (6%), or other (18%). The termed 'other' was given to EPOCH, CMED (cyclophosphamide, methotrexate, etoposide, and dexamethasone), gemcitabine-based, ifosfamide-based, and other therapies. Ten percent of patients underwent stem-cell transplantation (SCT) in the first remission. The overall response rate was 73% (61% complete), and 24% had the primary refractory disease (Abramson et al., 2014).

In Japan, the primary treatment of PTCL is CHOP that has a response rate of 50-65% (Kitazume et al., 2019). However, patients who are resistant to this therapy have an extremely poor prognosis. Standard line therapy for R/R PTCL is not established; however, pralatrexate, combination chemotherapy, brentuximab, and romidepsin are used.

The approved therapies for the treatment of PTCL in Japan includes Istodax (romidepsin), Folotyn (pralatrexate), Poteligeo (mogamulizumab), Adcetris (brentuximab vedotin), Mundesine (forodesine hydrochloride), and Arranon (nelarabine).

According to DelveInsight, PTCL market is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the PTCL 7MM market.

  • The market size of PTCL the seven major markets was found to be USD 815.38 Million in 2017.
  • According to DelveInsight estimates, the United States accounts for the largest market size of PTCL, in comparison to Japan and EU5 (Germany, France, Italy, Spain, and United Kingdom).
  • Among the EU5 countries, Germany had the highest market size in 2017.
  • Among 7MM, Japan accounts for the second-highest market size during the forecast period 2017-2030.

Market Outlook for Seven Major Markets

This section provides the total PTCL market size and market size by therapies in the United States, Germany, France, Italy, Spain, United Kingdom, and Japan.

Peripheral T-cell Lymphoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs that are expected to get launched in the market during the study period 2017-2030. The analysis covers PTCL market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Peripheral T-cell Lymphoma Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for PTCL emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the PTCL market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of PTCL, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the PTCL epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for PTCL is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of PTCL market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM PTCL market.

Report Highlights:

  • The seven major PTCL market is anticipated to increase with a CAGR of 8.43% for the study period 2017-2030.
  • The United States accounted for 53.58% of the market share in the 7MM.
  • Adcetris and Istodax (Romidepsin) for the first line treatment of PTCL is projected to lead the market with the highest market share in 2030.
  • In the coming years, PTCL market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence PTCL R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for PTCL. Launch of emerging therapies will significantly impact the PTCL market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

PTCL Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Sciatica Pipeline Analysis
  • Sciatica Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

PTCL Report Key Strengths

  • 11-Years Forecast
  • 7MMCoverage
  • PTCL Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

PTCL Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the PTCL market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the PTCL total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest PTCL market size during the forecast period (2020-2030)?
  • At what CAGR, the PTCL market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the PTCL market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the PTCL market growth until 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of PTCL?
  • What is the historical PTCL patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of PTCL at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PTCL?
  • Out of the countries mentioned above, which country would have the highest incident population of PTCL during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of PTCL along with the approved therapy?
  • What are the current treatment guidelines for the treatment of PTCL in the US and Europe?
  • What are the PTCL marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of PTCL?
  • How many therapies are developed by each company for the treatment of PTCL?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of PTCL?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the PTCL therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for PTCL and their status?
  • What are the key designations that have been granted for the emerging therapies for PTCL?
  • What are the 7MM historical and forecasted market of PTCL?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the PTCL.
  • To understand the future market competition in the PTCL market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for PTCL in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for PTCL market.
  • To understand the future market competition in the PTCL market.

Table of Contents

1. Key Insights

2. Executive Summary of Peripheral T-cell Lymphoma (PTCL)

3. Peripheral T-cell Lymphoma (PTCL) Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of Peripheral T-cell Lymphoma (PTCL) in 2017
  • 3.2. Market Share (%) Distribution of Peripheral T-cell Lymphoma (PTCL) in 2030

4. Disease Background and Overview: Peripheral T-cell Lymphoma (PTCL)

  • 4.1. Introduction
  • 4.2. Classification of PTCL
    • 4.2.1. WHO Classification System
  • 4.3. Subtypes of PTCL
    • 4.3.1. Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS)
    • 4.3.2. Anaplastic Large Cell Lymphoma (ALCL)
    • 4.3.3. Angioimmunoblastic T-Cell Lymphoma (AITL)
  • 4.4. Signs and Symptoms
  • 4.5. Cause of PTCL
  • 4.6. Pathophysiology
  • 4.7. Other conditions that can mimic PTCL
  • 4.8. Staging
  • 4.9. Diagnosis
    • 4.9.1. Blood tests
    • 4.9.2. Diagnostic Scans

5. Case Reports

  • 5.1. A case of peripheral T-cell lymphoma, not otherwise specified in an HCV and HTLV-II-positive patient, diagnosed by abdominal fluid cytology
  • 5.2. Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) presenting as an endobronchial lesion
  • 5.3. Peripheral T-cell Lymphoma with eosinophilia presenting as monoarthritis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. KOL Views
  • 6.3. Epidemiology Methodology
  • 6.4. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM

7. United States Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States
  • 7.3. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States
  • 7.4. Subtype-specific Incident cases of Peripheral T-cell Lymphoma (PTCL) in the United States

8. EU5 Epidemiology

  • 8.1. Assumptions and Rationale
  • 8.2. Germany Epidemiology
    • 8.2.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany
    • 8.2.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany
    • 8.2.3. Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany
  • 8.3. France Epidemiology
    • 8.3.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France
    • 8.3.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France
    • 8.3.3. Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France
  • 8.4. Italy Epidemiology
    • 8.4.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy
    • 8.4.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy
    • 8.4.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy
  • 8.5. Spain Epidemiology
    • 8.5.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain
    • 8.5.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain
    • 8.5.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain
  • 8.6. United Kingdom Epidemiology
    • 8.6.1. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK
    • 8.6.2. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK
    • 8.6.3. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK

9. Japan Epidemiology

  • 9.1. Assumptions and Rationale
  • 9.2. Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan
  • 9.3. Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan
  • 9.4. Subtype-specific Diagnosed Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan

10. Treatment

  • 10.1. Treatment Goals
    • 10.1.1. Treatment for Newly Diagnosed Patients
    • 10.1.2. Treatment for Patients with Relapsed or Refractory PTCL
  • 10.2. Treatment Options
    • 10.2.1. Chemotherapy
    • 10.2.2. Radiotherapy
    • 10.2.3. Steroids
    • 10.2.4. Bone marrow transplantation or Stem cell transplantation
    • 10.2.5. Medications
    • 10.2.6. Therapeutic Approaches
  • 10.3. Prospective Treatments
    • 10.3.1. PI3 kinase pathway
    • 10.3.2. Epigenetic therapies
    • 10.3.3. Antibody-based therapies
    • 10.3.4. Immune checkpoint inhibitors
  • 10.4. Personalized Treatment and Biomarkers
  • 10.5. Conclusion
  • 10.6. Treatment Guidelines
    • 10.6.1. United States
    • 10.6.2. Europe

11. Unmet needs

12. Marketed Drugs

  • 12.1. Beleodaq (Belinostat): Onxeo S.A.
    • 12.1.1. Drug Description
    • 12.1.2. Mechanism of Action
    • 12.1.3. Other development Activities
    • 12.1.4. Clinical Trial Information
    • 12.1.5. Advantages & Disadvantages
    • 12.1.6. Safety and Efficacy of Beleodaq
    • 12.1.7. Product Profile
  • 12.2. Istodax (Romidepsin): Celgene Corporation
    • 12.2.1. Drug Description
    • 12.2.2. Mechanism of Action
    • 12.2.3. Other Developmental Activities
    • 12.2.4. Clinical Trial Information
    • 12.2.5. Advantages and Disadvantages
    • 12.2.6. Safety and Efficacy of Istodax
    • 12.2.7. Product Profile
  • 12.3. Folotyn (Pralatrexate): Spectrum Pharmaceuticals
    • 12.3.1. Drug Description
    • 12.3.2. Mechanism of Action
    • 12.3.3. Other Developmental Activities
    • 12.3.4. Clinical Trial Information
    • 12.3.5. Advantages & Disadvantages
    • 12.3.6. Safety and Efficacy of Folotyn
    • 12.3.7. Product Profile
  • 12.4. Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
    • 12.4.1. Drug Description
    • 12.4.2. Mechanism of Action
    • 12.4.3. Other Developmental Activities
    • 12.4.4. Clinical Trial Information
    • 12.4.5. Advantages & Disadvantages
    • 12.4.6. Safety and Efficacy of Poteligeo
    • 12.4.7. Product Profile
  • 12.5. Adcetris (Brentuximab vedotin): Seattle Genetics
    • 12.5.1. Drug Description
    • 12.5.2. Mechanism of Action
    • 12.5.3. Other Developmental Activities
    • 12.5.4. Clinical Trial Information
    • 12.5.5. Advantages & Disadvantages
    • 12.5.6. Safety and Efficacy of Adcetris
    • 12.5.7. Product Profile
  • 12.6. Mundesine (Forodesine Hydrochloride): Mundipharma K. K.
    • 12.6.1. Drug Description
    • 12.6.2. Mechanism of Action
    • 12.6.3. Other Developmental Activities
    • 12.6.4. Clinical Trial Information
    • 12.6.5. Safety and Efficacy
    • 12.6.6. Product Profile
  • 12.7. Rituxan (MabThera): Genentech
    • 12.7.1. Drug Description
    • 12.7.2. Mechanism of Action
    • 12.7.3. Clinical Trial Information
    • 12.7.4. Advantages and Disadvantages
    • 12.7.5. Safety and Efficacy of Rituxan
    • 12.7.6. Product Profile
  • 12.8. Arranon (nelarabine): GlaxoSmithKline
    • 12.8.1. Product Description
    • 12.8.2. Regulatory Milestones
    • 12.8.3. Safety and Efficacy
    • 12.8.4. Product Profile

13. Emerging Drugs

  • 13.1. Key Cross Competition
  • 13.2. Denileukin diftitox: Eisai
    • 13.2.1. Product Description
    • 13.2.2. Other Developmental Activities
    • 13.2.3. Clinical Development
    • 13.2.4. Safety and Efficacy
    • 13.2.5. Product Profile
  • 13.3. SP-02 (Darinaparsin, ZIO-101): Solasia Pharma
    • 13.3.1. Product Description
    • 13.3.2. Other Developmental Activities
    • 13.3.3. Clinical Development
    • 13.3.4. Safety and Efficacy
    • 13.3.5. Product Profile
  • 13.4. Fenretinide (4-HPR): CerRx
    • 13.4.1. Product Description
    • 13.4.2. Other Developmental Activities
    • 13.4.3. Clinical Development
    • 13.4.4. Safety and Efficacy
    • 13.4.5. Product Profile
  • 13.5. Tipifarnib: Kura Oncology
    • 13.5.1. Product Description
    • 13.5.2. Other Developmental Activities
    • 13.5.3. Clinical Development
    • 13.5.4. Safety and Efficacy
    • 13.5.5. Product Profile
  • 13.6. HBI-8000: HUYA Bioscience International/Quintiles, Inc.
    • 13.6.1. Product Description
    • 13.6.2. Other Developmental Activities
    • 13.6.3. Clinical Development
    • 13.6.4. Safety and Efficacy
    • 13.6.5. Product Profile
  • 13.7. COPIKTRA (Duvelisib): Verastem
    • 13.7.1. Product Description
    • 13.7.2. Other Developmental Activities
    • 13.7.3. Clinical Development
    • 13.7.4. Safety and Efficacy
    • 13.7.5. Product Profile
  • 13.8. Genolimzumab (GB226): Genor Biopharma
    • 13.8.1. Product Description
    • 13.8.2. Other Developmental Activities
    • 13.8.3. Clinical Development
    • 13.8.4. Safety and Efficacy
    • 13.8.5. Product Profile
  • 13.9. Azacitidine (CC-486): Celgene Corporation
    • 13.9.1. Product Description
    • 13.9.2. Other Developmental Activities
    • 13.9.3. Clinical Development
    • 13.9.4. Product Profile
  • 13.10. Tislelizumab: BeiGene
    • 13.10.1. Product Description
    • 13.10.2. Other Developmental Activities
    • 13.10.3. Clinical Development
    • 13.10.4. Safety and Efficacy
    • 13.10.5. Product Profile
  • 13.11. Lacutamab/IPH4102: Innate Pharma
    • 13.11.1. Product Description
    • 13.11.2. Other Developmental Activities
    • 13.11.3. Clinical Development
    • 13.11.4. Product Profile
  • 13.12. AFM13: Affimed GmbH
    • 13.12.1. Product Description
    • 13.12.2. Other Developmental Activities
    • 13.12.3. Clinical Development
    • 13.12.4. Product Profile
  • 13.13. Opdivo (nivolumab) + Cabiralizumab: Bristol-Myers Squibb
    • 13.13.1. Product Description
    • 13.13.2. Other Developmental Activity
    • 13.13.3. Clinical Development
    • 13.13.4. Product Profile
  • 13.14. Bavencio (avelumab): Pfizer
    • 13.14.1. Product Description
    • 13.14.2. Clinical Development
    • 13.14.3. Product Profile
  • 13.15. Keytruda (pembrolizumab): Merck Sharp & Dohme Corp.
    • 13.15.1. Product Description
    • 13.15.2. Clinical Development
    • 13.15.3. Safety and Efficacy
    • 13.15.4. Product Profile
  • 13.16. STI-3031/IMC-001: Sorrento Therapeutics
    • 13.16.1. Product Description
    • 13.16.2. Other Developmental Activities
    • 13.16.3. Clinical Development
    • 13.16.4. Product Profile
  • 13.17. ALRN 6924: Aileron Therapeutics
    • 13.17.1. Product Description
    • 13.17.2. Other Developmental Activities
    • 13.17.3. Clinical Development
    • 13.17.4. Safety and Efficacy
    • 13.17.5. Product Profile
  • 13.18. Masitinib: AB Science
    • 13.18.1. Product Description
    • 13.18.2. Clinical Development
    • 13.18.3. Product Profile
  • 13.19. Ruxolitinib: Incyte Corporation/Novartis
    • 13.19.1. Product Description
    • 13.19.2. Other Developmental Activities
    • 13.19.3. Clinical Development
    • 13.19.4. Safety and Efficacy
    • 13.19.5. Product Profile
  • 13.20. Aplidin (plitidepsin): PharmaMar
    • 13.20.1. Product Description
    • 13.20.2. Other Developmental Activities
    • 13.20.3. Clinical Development
    • 13.20.4. Safety and Efficacy
    • 13.20.5. Product Profile
  • 13.21. ASTX660: Otsuka Pharmaceutical/Astex Pharmaceuticals
    • 13.21.1. Product Description
    • 13.21.2. Other Developmental Activities
    • 13.21.3. Clinical Development
    • 13.21.4. Safety and Efficacy
    • 13.21.5. Product Profile

14. Peripheral T-cell Lymphoma (PTCL): Seven Major Market Analysis

  • 14.1. Key Findings
  • 14.2. Market Methodology
  • 14.3. Market Size of Peripheral T-cell Lymphoma (PTCL) in the 7MM
  • 14.4. Market Size of Peripheral T-cell Lymphoma (PTCL) by Therapies in the 7MM
    • 14.4.1. Market Size of Peripheral T-cell Lymphoma (PTCL) by First-line Therapies in the 7MM
    • 14.4.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by Second-line Therapies in the 7MM

15. CD30 expression in peripheral T-cell lymphomas

16. Expected Launch Year of Emerging Therapies

17. Attribute Analysis Phase III

18. Attribute Analysis Phase II

19. United States Market Outlook

  • 19.1. United States Market Size
    • 19.1.1. Total market size of Peripheral T-cell Lymphoma (PTCL) in the United States
    • 19.1.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by Therapies in the United States

20. EU-5 Market Outlook

  • 20.1. Germany Market Size
    • 20.1.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in Germany
    • 20.1.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in Germany
  • 20.2. France Market Size
    • 20.2.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in France
    • 20.2.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in France
  • 20.3. Italy Market Size
    • 20.3.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in Italy
    • 20.3.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in Italy
  • 20.4. Spain Market Size
    • 20.4.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in Spain
    • 20.4.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in Spain
  • 20.5. United Kingdom Market Size
    • 20.5.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in the United Kingdom
    • 20.5.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in the UK

21. Japan Market Outlook

  • 21.1. Japan Market Size
    • 21.1.1. Total Market size of Peripheral T-cell Lymphoma (PTCL) in Japan
    • 21.1.2. Market Size of Peripheral T-cell Lymphoma (PTCL) by therapies in Japan

22. Market Drivers

23. Market Barriers

24. SWOT Analysis

25. Reimbursement and Market Access

26. Recognized Establishments

27. Appendix

  • 27.1. Bibliography
  • 27.2. Report Methodology

28. DelveInsight Capabilities

29. Disclaimer

30. About DelveInsight

List of Tables

  • Table 1: Summary of Peripheral T-cell Lymphoma (PTCL), Market, Epidemiology and Key Events (2017-2030)
  • Table 2: Old and New WHO classifications of PTCLs
  • Table 3: Subtypes of PTCL
  • Table 4: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM (2017-2030)
  • Table 5: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017-2030)
  • Table 6: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017-2030)
  • Table 7: Subtype-specific Incident Cases of PTCL in the US (2017-2030)
  • Table 8: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017-2030)
  • Table 9: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017-2030)
  • Table 10: Subtype-specific Incident Cases of PTCL in Germany (2017-2030)
  • Table 11: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017-2030)
  • Table 12: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017-2030)
  • Table 13: Subtype-specific Incident Cases of PTCL in France (2017-2030)
  • Table 14: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017-2030)
  • Table 15: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017-2030)
  • Table 16: Subtype-specific Incident Cases of PTCL in Italy (2017-2030)
  • Table 17: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017-2030)
  • Table 18: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017-2030)
  • Table 19: Subtype-specific Incident Cases of PTCL in Spain (2017-2030)
  • Table 20: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017-2030)
  • Table 21: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017-2030)
  • Table 22: Subtype-specific Incident Cases of PTCL in the United Kingdom (2017-2030)
  • Table 23: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017-2030)
  • Table 24: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017-2030)
  • Table 25: Subtype-specific Incident Cases of PTCL in Japan (2017-2030)
  • Table 26: Treatment for Patients with Relapsed or Refractory PTCL
  • Table 27: Beleodaq, Clinical Trial Description, 2020
  • Table 28: Istodax (Romidepsin), Clinical Trial Description, 2020
  • Table 29: Folotyn (Pralatrexate): Clinical Trial Description, 2020
  • Table 30: Poteligeo (Mogamulizumab): Clinical Trial Description, 2020
  • Table 31: Adcetris (Brentuximab vedotin): Clinical Trial Description, 2020
  • Table 32: Mundesine (Forodesine Hydrochloride): Clinical Trial Description, 2020
  • Table 33: Rituxan (MabThera): Clinical Trial Description, 2020
  • Table 34: Comparison of emerging drugs under development
  • Table 35: Denileukin diftitox (DD), Clinical Trial Description, 2020
  • Table 36: SP-02 (darinaparsin), Clinical Trial Description, 2020
  • Table 37: Fenretinide, Clinical Trial Description, 2020
  • Table 38: Tipifarnib, Clinical Trial Description, 2020
  • Table 39: HBI-8000, Clinical Trial Description, 2020
  • Table 40: COPIKTRA (Duvelisib), Clinical Trial Description, 2020
  • Table 41: Genolimzumab (GB226), Clinical Trial Description, 2020
  • Table 42: Azacitidine (CC-486), Clinical Trial Description, 2020
  • Table 43: Tislelizumab (BGB-A317), Clinical Trial Description, 2020
  • Table 44: Lacutamab (IPH4102), Clinical Trial Description, 2020
  • Table 45: AFM13, Clinical Trial Description, 2020
  • Table 46: Opdivo + Cabiralizumab, Clinical Trial Description, 2020
  • Table 47: Bavencio, Clinical Trial Description, 2020
  • Table 48: Keytruda, Clinical Trial Description, 2020
  • Table 49: STI-3031, Clinical Trial Description, 2020
  • Table 50: ALRN-6924, Clinical Trial Description, 2020
  • Table 51: Masitinib, Clinical Trial Description, 2020
  • Table 52: Ruxolitinib, Clinical Trial Description, 2020
  • Table 53: Aplidin, Clinical Trial Description, 2020
  • Table 54: ASTX660, Clinical Trial Description, 2020
  • Table 55: Market Size of Peripheral T-cell Lymphoma (PTCL) in the 7MM in USD Million (2017-2030)
  • Table 56: Market Size of Peripheral T-cell Lymphoma (PTCL) by first-line therapies in the 7MM, in USD Million (2017-2030)
  • Table 57: Market Size of Peripheral T-cell Lymphoma (PTCL) by second-line therapies in the 7MM, in USD Million (2017-2030)
  • Table 58: Expected Launch Year of Potential Emerging Therapies
  • Table 59: The US Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017-2030)
  • Table 60: Market Size of PTCL by First-line therapies in the US, in USD Million (2017-2030)
  • Table 61: Market Size of PTCL by Second-line therapies in the US, in USD Million (2017-2030)
  • Table 62: Germany Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017-2030)
  • Table 63: Market Size of PTCL by First-line therapies in Germany, in USD Million (2017-2030)
  • Table 64: Market Size of PTCL by Second-line therapies in Germany, in USD Million (2017-2030)
  • Table 65: France Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017-2030)
  • Table 66: Market Size of PTCL by First-line therapies in France, in USD Million (2017-2030)
  • Table 67: Market Size of PTCL by Second-line therapies in France, in USD Million (2017-2030)
  • Table 68: Italy Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017-2030)
  • Table 69: Market Size of PTCL by First-line therapies in Italy, in USD Million (2017-2030)
  • Table 70: Market Size of PTCL by Second-line therapies in Italy, in USD Million (2017-2030)
  • Table 71: Spain Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017-2030)
  • Table 72: Market Size of PTCL by First-line therapies in Spain, in USD Million (2017-2030)
  • Table 73: Market Size of PTCL by Second-line therapies in Spain, in USD Million (2017-2030)
  • Table 74: The UK Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017-2030)
  • Table 75: Market Size of PTCL by First-line therapies in the UK, in USD Million (2017-2030)
  • Table 76: Market Size of PTCL by Second-line therapies in the UK, in USD Million (2017-2030)
  • Table 77: Japan Market Size of Peripheral T-cell Lymphoma (PTCL) in USD Million (2017-2030)
  • Table 78: Market Size of PTCL by First-line therapies in Japan, in USD Million (2017-2030)
  • Table 79: Market Size of PTCL by Second-line therapies in Japan, in USD Million (2017-2030)

List of Figures

  • Figure 1: Classification of PTCL
  • Figure 2: T-cell neoplasms: organ of origin or involvement and associated chromosomal and genetic alterations.
  • Figure 3: KOL Views
  • Figure 4: KOL Views
  • Figure 5: KOL Views
  • Figure 6: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the 7MM (2017-2030)
  • Figure 7: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017-2030)
  • Figure 8: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the United States (2017-2030)
  • Figure 9: Subtype-specific Incident cases of Peripheral T-cell Lymphoma (PTCL) in the US (2017-2030)
  • Figure 10: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017-2030)
  • Figure 11: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017-2030)
  • Figure 12: Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Germany (2017-2030)
  • Figure 13: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017-2030)
  • Figure 14: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017-2030)
  • Figure 15: Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in France (2017-2030)
  • Figure 16: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017-2030)
  • Figure 17: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017-2030)
  • Figure 18: Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Italy (2017-2030)
  • Figure 19: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017-2030)
  • Figure 20: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017-2030)
  • Figure 21: Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Spain (2017-2030)
  • Figure 22: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017-2030)
  • Figure 23: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017-2030)
  • Figure 24: Subtype-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in the UK (2017-2030)
  • Figure 25: Total Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017-2030)
  • Figure 26: Stage-specific Incident Cases of Peripheral T-cell Lymphoma (PTCL) in Japan (2017-2030)
  • Figure 27: Subtype-specific Incident Cases of PTCL in Japan (2017-2030)
  • Figure 28: First Line of therapy for PTCL-NOS
  • Figure 29: Second Line of therapy for PTCL-NOS with Stem cell transplant
  • Figure 30: First Line of therapy for ALCL, ALK+
  • Figure 31: Second Line of therapy for ALCL- ALK+ with Stem cell transplant
  • Figure 32: First Line of therapy for ALCL-ALK
  • Figure 33: Second Line of therapy for ALCL-ALK- with Stem cell transplant
  • Figure 34: First Line of therapy for AICL
  • Figure 35: Second Line of therapy for AICL with Stem cell transplant
  • Figure 36: First Line of therapy for EATCL
  • Figure 37: Second Line of therapy for enetropathy associated T cell lymphoma with stem cell transplantation
  • Figure 38: Integrated Management Algorithm for PTCL
  • Figure 39: Treatment for relapsed/ refractory Nodal and Extranodal Peripheral T-cell Lymphoma
  • Figure 40: Unmet Needs of PTCL
  • Figure 41: Market Size of Peripheral T-cell Lymphoma (PTCL) in the 7MM in USD Million (2017-2030)
  • Figure 42: Market Size of Peripheral T-cell Lymphoma (PTCL) by first-line therapies in the 7MM, in USD Million (2017-2030)
  • Figure 43: Market Size of Peripheral T-cell Lymphoma (PTCL) by second-line therapies in the 7MM, in USD Million (2017-2030)
  • Figure 44: Market Size of Peripheral T-cell Lymphoma (PTCL) in the US, USD Millions (2017-2030)
  • Figure 45: Market Size of PTCL by First-line therapies in the US, in USD Million (2017-2030)
  • Figure 46: Market Size of PTCL by Second-line therapies in the US, in USD Million (2017-2030)
  • Figure 47: Market Size of Peripheral T-cell Lymphoma (PTCL) in Germany, USD Millions (2017-2030)
  • Figure 48: Market Size of PTCL by First-line therapies in Germany, in USD Million (2017-2030)
  • Figure 49: Market Size of PTCL by Second-line therapies in Germany, in USD Million (2017-2030)
  • Figure 50: Market Size of Peripheral T-cell Lymphoma (PTCL) in France, USD Millions (2017-2030)
  • Figure 51: Market Size of PTCL by First-line therapies in France, in USD Million (2017-2030)
  • Figure 52: Market Size of PTCL by Second-line therapies in France, in USD Million (2017-2030)
  • Figure 53: Market Size of Peripheral T-cell Lymphoma (PTCL) in Italy, USD Millions (2017-2030)
  • Figure 54: Market Size of PTCL by First-line therapies in Italy, in USD Million (2017-2030)
  • Figure 55: Market Size of PTCL by Second-line therapies in Italy, in USD Million (2017-2030)
  • Figure 56: Market Size of Peripheral T-cell Lymphoma (PTCL) in Spain, USD Millions (2017-2030)
  • Figure 57: Market Size of PTCL by First-line therapies in Spain, in USD Million (2017-2030)
  • Figure 58: Market Size of PTCL by Second-line therapies in Spain, in USD Million (2017-2030)
  • Figure 59: Market Size of Peripheral T-cell Lymphoma (PTCL) in the UK, USD Millions (2017-2030)
  • Figure 60: Market Size of PTCL by First-line therapies in the UK, in USD Million (2017-2030)
  • Figure 61: Market Size of PTCL by Second-line therapies in the UK, in USD Million (2017-2030)
  • Figure 62: Market Size of Peripheral T-cell Lymphoma (PTCL) in Japan, USD Millions (2017-2030)
  • Figure 63: Market Size of PTCL by First-line therapies in Japan, in USD Million (2017-2030)
  • Figure 64: Market Size of PTCL by Second-line therapies in Japan, in USD Million (2017-2030)
  • Figure 65: Market Drivers
  • Figure 66: Market Barriers
  • Figure 67: SWOT Analysis of Peripheral T-Cell Lymphoma (PTCL)